Clinical Trials Sponsored by Bioven Europe

Total 4156 results

Biogen

Completed

Demonstrate the Bioequivalence of Interferon Beta-1a (INFB) Manufactured by Two Different Processes in Healthy Volunteers

Multiple Sclerosis

United States
Biogen

Completed

Safety and Efficacy of IDEC-114 in the Treatment of Non-Hodgkin's Lymphoma

Non-Hodgkin's Lymphoma

United States
Biogen

Completed

COMPliance With Avonex® PS in Patients With Relapsing-Remitting MS (COMPASS)

Multiple Sclerosis, Relapsing-Remitting

Canada
Biogen

Terminated

A Safety Study in Healthy Volunteers of the Single-Use Autoinjector Containing Placebo of BG9418 Interferon Beta-1a With a 25-Gauge × 1-Inch Needle

Healthy

Canada
Biogen

Terminated

Mechanism of Action of Galiximab in Subjects With Previously Untreated Follicular Non-Hodgkin's Lymphoma

Lymphoma, Non-Hodgkin's

United States
Biogen

Completed

Simvastatin as an Add-on Treatment to Interferon-beta-1a for the Treatment of Relapsing-Remitting Multiple Sclerosis (SIMCOMBIN)

Multiple Sclerosis

Denmark
Biogen

Completed

BIIB014 Cardiovascular Monitoring Study

Healthy

United States
Biogen

Terminated

Phase 1, Dose-Escalation, Pharmacodynamic Study of IV CNF1010 in ZAP-70 Positive CLL

Chronic Lymphocytic Leukemia

United States
Biogen

Completed

Avonex 15 Year Long Term Follow-up Study (15yASSURANCE)

Multiple Sclerosis

United States
Biogen

Completed

Pharmacokinetics Profile Study of BG00012 Standard Formulation and BG00012 Active Pharmaceutical Ingredient

Healthy
Biogen

Completed

A Multicenter Study to Assess the Effect of Plasma Exchange in Accelerating the Clearance of Natalizumab in Subjects With Multiple Sclerosis (MS)

Relapsing Forms of Multiple Sclerosis

United States
Biogen

Completed

Open-Label Natalizumab Safety Extension Study

Multiple Sclerosis

United States
Biogen

Completed

Immunogenicity and Safety Study of Serum-Free Avonex

Multiple Sclerosis
Biogen

Terminated

Phase 1, Dose-Escalation Study of Oral CNF2024(BIIB021) in CLL

B-Cell Chronic Lymphocytic Leukemia

United States
Biogen

Completed

Dose-Finding Safety Study of BIIB014 in Early-Stage Parkinson's Disease (MOBILE)

Parkinson's Disease

Poland, Israel, Serbia
Biogen

Completed

Using PET Scans to Study Brain Receptor Occupancy of BIIB014 in Healthy Male Volunteers

Healthy

United Kingdom
Biogen

Completed

AVONEX® Combination Trial - "ACT"

Multiple Sclerosis, Relapsing-Remitting

United States
Biogen

Completed

Safety of Avonex Treatment in Multiple Sclerosis Patients With Neutralizing Antibodies to Interferon Beta Therapy (SAFE)

Multiple Sclerosis

Sweden
Biogen

Recruiting

A Study to Assess New Participant's Perspectives Beyond Clinical Efficacy of Monoclonal Antibody-Based Relapsing Remitting Multiple Sclerosis (RRMS) Treatments

Multiple Sclerosis, Relapsing-Remitting

United States
Biogen

Not yet recruiting

A Study of Omaveloxolone in Children With Friedreich's Ataxia

Friedreich Ataxia

United States
Biogen

Recruiting

A Study of Spinraza (Nusinersen) Exposure in Pregnant Women With Spinal Muscular Atrophy (SMA) Within Existing SMA Registries

Muscular Atrophy, Spinal

United States
Biogen

Recruiting

A Study of End of Dose Phenomena in Subcutaneous Natalizumab Treated Multiple Sclerosis (MS) Participants (SATURATE-MS)

Multiple Sclerosis

Germany
Biogen

Recruiting

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BIIB115

Healthy Volunteer | Muscular Atrophy, Spinal

Korea, Republic of, Germany, Belgium, Netherlands, Italy, Poland, Canada, France, United Kingdom, Israel
Biogen

Recruiting

Pediatric Spinal Muscular Atrophy (SMA) China Registry

Muscular Atrophy, Spinal

China
Biogen

Recruiting

A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus (TOPAZ-1)

Lupus Erythematosus, Systemic

United States, Australia, Korea, Republic of, Chile, Spain, Poland, Philippines, Taiwan, Greece, Brazil, Bulgaria, Mexico, France, Russian Federation, Sweden
Biogen

Recruiting

A Study of BIIB067 (Tofersen) Initiated in Clinically Presymptomatic Adults With a Confirmed Superoxide Dismutase 1 Mutation (ATLAS)

Amyotrophic Lateral Sclerosis Associated With a SOD1 Gene Mutation

United States, Canada, Spain, Australia, Germany, Italy, Japan, Korea, Republic of, United Kingdom, Belgium, Brazil, France, Poland, Sweden
Biogen

Completed

A Study to Explore Association Patterns Between Digital Outcome Assessments From the Konectom™ Platform and Magnetic Resonance Imaging (MRI) Measures of Brain Tissue Damage

Multiple Sclerosis (MS)

Germany
Biogen

Active, not recruiting

A Study of Multiple Doses of Nusinersen (ISIS 396443) Delivered to Infants With Genetically Diagnosed and Presymptomatic Spinal Muscular Atrophy (NURTURE)

Spinal Muscular Atrophy

United States, Taiwan, Israel, Australia, Qatar, United Kingdom, Turkey, Italy, Germany, Argentina, Canada
Biogen

Active, not recruiting

A Study of Dimethyl Fumarate (DMF) in Relapsing Forms of Multiple Sclerosis (RMS) Participants in China

Multiple Sclerosis

China
Biogen

Completed

Tysabri Observational Program (TOP)

Relapsing-Remitting Multiple Sclerosis

Belgium, Germany, Italy, Norway, France, Mexico, Australia, Spain, Portugal, Greece, Netherlands, United Kingdom, Czechia, Slovakia, Finland, Canada, Argentina, Brazil
Biogen

Completed

A Safety Study of Retinal Gene Therapy for Choroideremia With Administration of BIIB111 (GEMINI)

Choroideremia

United States, Germany, France
Biogen

Active, not recruiting

A Study to Evaluate Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of Natalizumab (BG00002) Administered Subcutaneously to Japanese Participants With Relapsing-Remitting Multiple Sclerosis

Multiple Sclerosis, Relapsing-Remitting

Japan
Biogen

Withdrawn

A Study to Evaluate the Efficacy and Safety of BIIB131 for Participants With Ischemic Stroke Between 4.5 and 24 Hours After Last Known Well (DAISY)

Ischemic Stroke
Biogen

Completed

A Study to Assess the Clinical Validity of Konectom™ in Adults Living With Neuromuscular Disorders (DigiNOA)

Spinal Muscular Atrophy

Germany
Biogen

Completed

A Comparative Study of Sage-217 Plus an Antidepressant (ADT) Versus Placebo Plus an ADT in Adults With Major Depressive Disorder

Depressive Disorder, Major

United States
Biogen

Completed

A Study to Evaluate the Efficacy of Sage-217 in the Treatment of Adult Participants With Major Depressive Disorder (MDD)

Depressive Disorder, Major

United States
Biogen

Completed

Non-Interventional, Postmarketing Surveillance Study of Nusinersen Sodium Injection (PANDA)

Muscular Atrophy, Spinal

China
Biogen

Completed

A Study to Evaluate SAGE-217 in Participants With Moderate to Severe Major Depressive Disorder

Major Depression

United States
Biogen

Terminated

A Pharmacodynamic Study of Measured Glomerular Filtration Rate in Patients With Chronic Kidney Disease and Type 2 Diabetes

Type 2 Diabetes | Chronic Kidney Disease
Biogen

Completed

Real World Analysis on Lymphocyte Reconstitution After Lymphopenia in Participants Treated by Tecfidera (Lympho-TEC)

Multiple Sclerosis | Multiple Sclerosis, Relapsing-Remitting

France
Biogen

Completed

BIIB014 Effects on the Pharmacokinetics (PK) of Rosiglitazone, Warfarin, and Midazolam

Healthy

United Kingdom
Biogen

Completed

Safety and Tolerability of Repeat Courses of IM Alefacept

Chronic Plaque Psoriasis

United States, Germany, France, Canada, Austria, Denmark, Netherlands, Switzerland, United Kingdom
Biogen

Active, not recruiting

A Study Utilising Data From European Union (EU) National Multiple Sclerosis (MS) Registries to Assess the Incidence of Anti-Natalizumab Antibody Among Participants Who Receive Subcutaneous Administration of Natalizumab for Treatment of Relapsing-remitting Multiple Sclerosis (RRMS)

Multiple Sclerosis

United States
Biogen

Completed

A Study to Evaluate Safety, Tolerability, and Distribution of a Microdose of Radiolabeled BIIB067 (99mTc-MAG3-BIIB067) Co-administered With BIIB067 (Tofersen) to Healthy Adults

Healthy Volunteers

United States
Biogen

Terminated

Study to Evaluate the Efficacy and Safety of Dimethyl Fumarate (Tecfidera) and Peginterferon Beta-1a (Plegridy) for the Treatment of Relapsing-Remitting Multiple Sclerosis in Pediatric Participants

Multiple Sclerosis, Relapsing-Remitting

Mexico, Turkey, United States, Hungary, Taiwan, Thailand, Korea, Republic of, Saudi Arabia, Malaysia, Colombia, Estonia, Jordan, Tunisia
Biogen

Terminated

Study of Diroximel Fumarate in the Real-World Setting

Relapsing Forms of MS

United States
Biogen

Withdrawn

802NP301 Efficacy and Safety Study of BIIB074 in Participants With Trigeminal Neuralgia (SURGE-1)

Trigeminal Neuralgia
Biogen

Completed

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB100 Administered Orally to Adults With Amyotrophic Lateral Sclerosis

Amyotrophic Lateral Sclerosis

United States
Biogen

Completed

A Real-world Study of Imraldi® Use (PROPER)

Arthritis, Rheumatoid (RA) | Arthritis, Psoriatic (PsA) | Crohn's Disease (CD) | Colitis, Ulcerative (UC) | Axial Spondyloarthritis (axSpA)

Italy, United Kingdom, Germany, Belgium, Spain, Ireland
Biogen

Completed

MS PATHS COVID-19 Questionnaire Data Linkage Sub-Study

Multiple Sclerosis (MS)

United States

3

Subscribe